Clinical meaning
Generalized Anxiety Disorder (GAD) is characterized by persistent, excessive, and difficult-to-control worry about multiple life domains, with the DSM-5 requiring a minimum duration of 6 MONTHS to distinguish it from transient anxiety responses and adjustment disorders. The neurobiological basis involves dysregulation of the cortico-limbic anxiety circuit: the amygdala (threat detection center) becomes hyperactive with lowered activation threshold, while the prefrontal cortex (PFC — responsible for top-down regulation and worry suppression) shows impaired inhibitory control over amygdala output. This creates a feed-forward loop where the amygdala generates excessive fear responses that the PFC cannot adequately suppress. At the neurotransmitter level, GAD involves deficient GABAergic inhibition (GABA is the primary inhibitory neurotransmitter — benzodiazepines enhance GABA-A receptor function for acute relief), serotonergic dysregulation (reduced 5-HT1A receptor binding in the amygdala and raphe nuclei — SSRIs/SNRIs increase serotonergic tone over 4-8 weeks), and noradrenergic hyperactivity (excessive locus coeruleus firing contributes to hyperarousal, muscle tension, and autonomic symptoms). The 6-month duration criterion is clinically critical because it separates GAD (a chronic neurobiological disorder requiring sustained pharmacotherapy and psychotherapy) from adjustment disorder with anxiety (which...